var data={"title":"Azithromycin (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Azithromycin (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/387712?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=azithromycin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Azithromycin (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=azithromycin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Azithromycin (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983183\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zithromax;</li>\n      <li>Zithromax Tri-Pak;</li>\n      <li>Zithromax Z-Pak;</li>\n      <li>Zmax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983184\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zithromax;</li>\n      <li>Zmax SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10585820\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Macrolide</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12824328\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Extended release suspension (Zmax) is not interchangeable with immediate-release formulations. All oral doses are expressed as immediate release azithromycin unless otherwise specified. With oral therapy, monitor for infantile hypertrophic pyloric stenosis (IHPS).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 10 to 20 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chlamydial conjunctivitis or chlamydial pneumonia:</b> Limited data available: Oral: 20 mg/kg once daily for 3 days (CDC [Workowski 2015]; Hammerschlag 1998)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pertussis, treatment and postexposure prophylaxis</b>: Oral, IV: 10 mg/kg once daily for 5 days (<i>Red Book</i> [AAP 2012])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10585964\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=azithromycin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Azithromycin (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Extended release suspension (Zmax) is not interchangeable with immediate-release formulations. All doses are expressed as immediate release azithromycin unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP] 2012): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mild to moderate infection: Oral: 5 to 12 mg/kg/dose; typically administered as 10 to 12 mg/kg/dose on day 1 followed by 5 to 6 mg/kg once daily for remainder of treatment duration; usual maximum dose for the total course: 1,500 to 2,000 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Serious infection: IV: 10 mg/kg once daily; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Babesiosis:</b> Infants, Children, and Adolescents: Oral: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), then 5 mg/kg once daily on days 2 to 10 (maximum dose: 250 mg/dose) in combination with atovaquone; longer duration of therapy may be necessary in some cases; in immunocompromised patients, higher doses (eg, adults: 600 to 1,000 mg daily) may be required (<i>Red Book</i> [AAP] 2012; Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Bartonellosis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Cat scratch disease (<i>B. henselae</i>) with extensive lymphadenopathy (IDSA [Stevens] 2014): <i>Non-HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants, Children, and Adolescents &le;45 kg: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 5 mg/kg once daily on days 2 to 5 (maximum dose: 250 mg/dose) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children and Adolescents &gt;45 kg: 500 mg as a single dose on day 1, then 250 mg once daily for 4 additional days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Cutaneous bacillary angiomatosis (<i>B. henselae</i> or <i>B. quintana</i>): <i>HIV- exposed/-positive:</i> Infants, Children, and Adolescents: 5 to 12 mg/kg once daily; maximum dose: 600 mg/dose; usual treatment duration: 3 months (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Chancroid</b> (CDC 2010; <i>Red Book</i> [AAP] 2012): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&lt;45 kg: 20 mg/kg as a single dose; maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&ge;45 kg: 1,000 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Chlamydial infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Cervicitis, urethritis (<i>C. trachomatis</i>): Children and Adolescents &ge;45 kg: Oral: 1,000 mg as a single dose (CDC 2010; <i>Red Book</i> [AAP] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Conjunctivitis: Infants: Oral, IV: 20 mg/kg once daily for 3 days (<i>Red Book</i> [AAP] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pneumonia, community-acquired (Bradley 2011): Infants &gt;3 months, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Mild infection or step-down therapy: Oral: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose) followed by 5 mg/kg once daily on days 2 to 5 (maximum dose: 250 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Severe infection: IV: 10 mg/ kg once daily for at least 2 days, then transition to oral route with a single daily dose of 5 mg/kg to complete course of therapy; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Cystic fibrosis; improve lung function, reduce exacerbation frequency:</b> Limited data available; dosing regimen variable (Mogayzel 2013; Saiman 2003; Saiman 2010): Children &ge;6 years and Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">18 to 35.9 kg: 250 mg three times weekly (Monday, Wednesday, Friday)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&ge;36 kg: 500 mg three times weekly (Monday, Wednesday, Friday)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Diarrhea, infectious:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Campylobacter</i>: Infants, Children, and Adolescents: Oral: 10 mg/kg once daily for 3 days; maximum dose: 500 mg/dose (<i>Red Book</i> [AAP] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Shigellosis: Infants, Children, and Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">AAP Recommendation: 12 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 6 mg/kg once daily on days 2 to 5 (maximum dose: 250 mg/dose) (<i>Red Book</i> [AAP] 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Alternate dosing: 10 mg/kg once daily for 3 days (Dupont 2009; Mackell 2005); WHO Guidelines recommend up to 20 mg/kg/dose and in some cases, a wider range of duration of therapy (eg, 1 to 5 days) (WHO 2005) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Endocarditis; prophylaxis:</b> Infants, Children, and Adolescents: Oral: 15 mg/kg/dose 30 to 60 minutes before procedure; maximum dose: 500 mg/dose (Wilson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Gonococcal infection; uncomplicated (cervicitis, urethritis, anorectal):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &lt;45 kg: 20 mg/kg as a single dose; maximum dose: 1,000 mg/dose (<i>Red Book</i> [AAP] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &gt; 8 years and &ge;45 kg and Adolescents: 1,000 mg as a single dose (CDC 2012; <i>Red Book</i> [AAP] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Group A streptococcal infection; treatment of streptococcal tonsillopharyngitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer's labeling and AHA/AAP recommendations: Infants, Children, and Adolescents: Oral: 12 mg/kg/dose once daily for 5 days; maximum dose: 500 mg/dose (Gerber 2009; <i>Red Book</i> [AAP] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IDSA reconmendations: <b>Note:</b> Recommended as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients. Infants, Children, and Adolescents: Oral: 12 mg/kg (maximum: 500 mg/dose) on day 1 followed by 6 mg/kg/dose (maximum: 250 mg/dose) once daily on days 2 through 5 (Shulman 2012); Recommended by the Infectious Disease Society of America (IDSA) as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients (Shulman 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Three-day regimen: Limited data available: Children and Adolescents: Oral: 20 mg/kg/dose once daily for 3 days; maximum dose: 1000 mg/dose (Cohen 2004; O&rsquo;Doherty 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Meningococcal disease, chemoprophylaxis of high-risk contacts:</b> Infants, Children, and Adolescents: Oral: 10 mg/kg as a single dose; maximum dose: 500 mg/dose; <b>Note:</b> Not routinely recommended; may consider if fluoroquinolone resistance detected (<i>Red Book</i> [AAP] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Mycobacterium avium</i></b>\n      <b> complex (MAC) infection (HIV-exposed/-positive):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children (DHHS [pediatric] 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Treatment: 10 to 12 mg/kg once daily in combination with ethambutol, with or without rifabutin; maximum dose: 500 mg/dose; treatment duration at least 12 months; dependent upon clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Primary prevention of first episode: Preferred: 20 mg/kg once <b>weekly</b> (maximum dose: 1,200 mg/dose) <b>or</b> alternatively, 5 mg/kg once daily (maximum dose: 250 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Secondary prevention of recurring episodes: 5 mg/kg once daily in combination with ethambutol, with or without rifabutin; maximum dose: 250 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\"> Adolescents (DHHS [adult] 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Treatment: 500 to 600 mg daily in combination with ethambutol</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Primary prophylaxis: 1,200 mg once weekly <b>or</b> alternatively, 600 mg twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Secondary prophylaxis: 500 to 600 mg daily in combination with ethambutol</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Otitis media, acute (AOM):</b> Infants &ge;6 months, Children, and Adolescents: Oral: <b>Note:</b> Due to increased <i>S pneumonia</i> and <i>H. influenzae</i> resistance, azithromycin is not routinely recommended as a treatment option (AAP [Lieberthal 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Single dose regimen: 30 mg/kg as a single dose; maximum dose: 1,500 mg/dose; if patient vomits within 30 minutes of dose, repeat dosing has been administered although limited data available on safety</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Three-day regimen: 10 mg/kg once daily for 3 days; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Five-day regimen: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 5 mg/kg (maximum dose: 250 mg/dose) once daily on days 2 to 5</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Peritonitis (peritoneal dialysis), prophylaxis for patients receiving peritoneal dialysis who require dental procedures:</b> Infants, Children, and Adolescents: Oral: 15 mg/kg administered 30 to 60 minutes before dental procedure; maximum dose: 500 mg/dose (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pertussis</b> (CDC 2005; <i>Red Book</i> [AAP] 2012): Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 1 to 5 months: 10 mg/kg/dose once daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants &ge;6 months, Children, and Adolescents: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 5 mg/kg once daily on days 2 to 5 (maximum dose: 250 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pneumonia, community-acquired (excluding mycobacterial [<i>mycoplasma pneumoniae</i>] and chlamydial infections): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Immediate release: Infants &gt;3 months, Children, and Adolescents: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 5 mg/kg (maximum dose: 250 mg/dose) once daily on days 2 to 5 (Bradley 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Extended release oral suspension (Zmax): Infants &ge;6 months, Children, and Adolescents: 60 mg/kg as a single dose; maximum dose: 2,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: Infants &gt;3 months, Children, and Adolescents: 10 mg/kg once daily for at least 2 days, follow IV therapy by the oral route with a single daily dose of 5 mg/kg to complete a 5-day course of therapy; maximum dose: 500 mg/dose (Bradley 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pneumonia, community acquired; <i>mycoplasma pneumoniae</i>, or chlamydial infection</b> (Bradley 2011): Infants &gt;3 months, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mild infection or step-down therapy: Oral: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose) followed by 5 mg/kg once daily on days 2 to 5 (maximum dose: 250 mg/dose) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe infection: IV: 10 mg/kg once daily for at least 2 days (maximum dose: 500 mg/dose), then transition to oral route with a single daily dose of 5 mg/kg to complete course of therapy (maximum dose: 250 mg/dose) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Rhinosinusitis, bacterial:</b> Oral: Infants &ge;6 months, Children, and Adolescents: 10 mg/kg once daily for 3 days; maximum dose: 500 mg/dose; <b>Note:</b> Although FDA approved, macrolides are not recommended for empiric therapy due to high rates of resistance (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Sexual victimization, prophylaxis:</b> Oral: <b>Note:</b> Use in combination with cefixime or ceftriaxone and completion of hepatitis B virus immunization; also consider prophylaxis for trichomoniasis and bacterial vaginosis (CDC 2010; <i>Red Book</i> [AAP] 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &lt;45 kg: 20 mg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;45 kg and Adolescents: 1,000 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Toxoplasma gondii</i>, encephalitis (HIV-exposed/-positive); treatment and prevention:</b> Oral: Adolescents: 900 to 1,200 mg once daily in combination with pyrimethamine/leucovorin; treatment duration: 6 weeks or longer if extensive disease or incomplete response at 6 weeks (DHHS [adult] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Rhinosinusitis, bacterial:</b> Oral: 500 mg once daily for 3 days. <b>Note:</b> Although FDA approved, macrolides are not recommended for empiric therapy due to high rates of resistance (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate regimen: Extended release suspension (Zmax): 2,000 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Chancroid due to </b>\n      <b>\n        <i>H. ducreyi</i></b>: Oral: 1000 mg as a single dose (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Cervicitis, urethritis: Nongonococcal </b>\n      <b>\n        <i>Chlamydia trachomatis</i></b>: Oral: 1,000 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Gonococcal infection, uncomplicated (cervix, rectum, urethra): </b>Oral: 1,000 mg as a single dose in combination with ceftriaxone (preferred) or cefixime (only if ceftriaxone unavailable); if cefixime is used, test-of-cure in 7 days is recommended (CDC 2012). <b>Note:</b> Monotherapy with azithromycin single dose of 2,000 mg has been associated with resistance and/or treatment failure; however, may be appropriate for treatment of a gonococcal infection in pregnant women who cannot tolerate a cephalosporin (CDC 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Patients with severe cephalosporin allergy:</i> 2,000 mg as a single dose and test-of-cure in 7 days (CDC, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Gonococcal infection, uncomplicated (pharynx):</b> Oral: 1,000 mg as a single dose in combination with ceftriaxone (CDC 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Gonococcal infection, expedited partner therapy:</b> Oral: 1,000 mg as a single dose in combination with cefixime (CDC 2012). <b>Note:</b> Only used if a heterosexual partner cannot be linked to evaluation and treatment in a timely manner; dose delivered to partner by patient, collaborating pharmacy, or disease investigation specialist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Granuloma inguinale (donovanosis):</b> Oral: 1000 mg once a week for at least 3 weeks and until lesions have healed (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Endocarditis prophylaxis:</b> Oral: 500 mg 30 to 60 minutes before procedure. <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA (Wilson 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Mild to moderate respiratory tract, skin, and soft tissue infections:</b> Oral: 500 mg in a single loading dose on day 1 followed by 250 mg daily as a single dose on days 2 to 5</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Alternative regimen:</i> Bacterial exacerbation of COPD: 500 mg daily for a total of 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Mycobacterium avium</i></b>\n      <b> complex disease, disseminated, in patients with advanced HIV infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Treatment: 600 mg daily in combination with ethambutol</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Primary prophylaxis: 1,200 mg once weekly (preferred), with <b>or</b> without rifabutin or alternatively, 600 mg twice weekly (DHHS [adult] 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Secondary prophylaxis: 500 to 600 mg daily in combination with ethambutol (DHHS [adult] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pelvic inflammatory disease:</b> IV: 500 mg as a single dose for 1 to 2 days, follow IV therapy by the oral route with a single daily dose of 250 mg to complete a 7-day course of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pharyngitis/tonsillitis, group A streptococci:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer labeling: Oral: 500 mg on day 1 followed by 250 mg once daily on days 2 to 5</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IDSA guidelines: Oral: 12 mg/kg (maximum: 500 mg) on day 1 followed by 6 mg/kg/dose (maximum: 250 mg) once daily days 2 to 5. <b>Note:</b> Recommended by the Infectious Disease Society of America (IDSA) as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients (Shulman 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pneumonia, community-acquired:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 500 mg on day 1 followed by 250 mg once daily on days 2 to 5</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Alternate regimen:</i> Extended release suspension (Zmax): 2,000 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 500 mg as a single dose for at least 2 days; follow IV therapy by the oral route with a single daily dose of 500 mg to complete a 7- to 10-day course of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pertussis:</b> Oral: 500 mg on day 1 followed by 250 mg once daily on days 2 to 5 (CDC 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault:</b> Oral: 1,000 mg as a single dose (in combination with a cephalosporin and metronidazole) (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants &ge;6 months, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Use with caution in patients with GFR &lt;10 mL/minute (AUC increased by 35% compared to patients with normal renal function); however, no dosage adjustment is provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">No supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (Aronoff 2007; Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Azithromycin is predominantly hepatically eliminated; however, there is no dosage adjustment provided in the manufacturer's labeling. Use with caution due to potential for hepatotoxicity (rare); discontinue immediately for signs or symptoms of hepatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983340\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 1 g (3 ea, 10 ea) [cherry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (3 ea, 10 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 2.5 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 100 mg/5 mL (15 mL) [cherry-vanilla-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 200 mg/5 mL (15 mL, 22.5 mL, 30 mL) [cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zmax: 2 g (1 ea) [cherry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (15 mL); 200 mg/5 mL (15 mL, 22.5 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 250 mg, 500 mg, 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax Tri-Pak: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax Z-Pak: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 600 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983186\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10585984\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: May administer without regard to food; do not administer with antacids that contain aluminum or magnesium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension, multiple doses: Shake well before use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension 1,000 mg packet for a single dose: Administer the entire contents immediately after mixing; add an additional 60 mL of water, mix, and drink. Do not use to administer any other dose except 1,000 mg or 2,000 mg. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release oral suspension: Shake suspension well before use; administer on an empty stomach 1 hour before or 2 hours after a meal; must be administered within 12 hours of reconstitution. May be administered without regard to antacids containing aluminum or magnesium. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Do not give IM or by direct IV injection.</b> Administer IV infusion at a final concentration of 1 mg/mL over 3 hours; for a 2 mg/mL concentration, infuse over 1 hour; do not infuse over a period of less than 60 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983256\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection (Zithromax): Store intact vials of injection at room temperature. Reconstituted solution is stable for 24 hours when stored below 30&deg;C (86&deg;F). The diluted solution D5W, D5LR, D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>3</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS (with or without 20 mEq/L KCl), Normosol-M in D5, Normosol-R in D5, LR, NS, or <sup>1</sup>/<sub>2</sub>NS is stable for 24 hours at or below room temperature (30&deg;C [86&deg;F]) and for 7 days if stored under refrigeration (5&deg;C [41&deg;F]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, immediate release (Zithromax): Store dry powder below 30&deg;C (86&deg;F). Store reconstituted suspension at 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F) and use within 10 days. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, extended release (Zmax): Store dry powder &le;30&deg;C (86&deg;F). Following reconstitution, store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not refrigerate or freeze. Should be consumed within 12 hours following reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet (Zithromax): Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10585821\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release; oral suspension, tablets: Treatment of acute otitis media due to <i>H. influenzae</i>, <i>M. catarrhalis</i>, or <i>S. pneumoniae</i> (FDA approved in pediatric patient ages &ge;6 months); treatment of pharyngitis/tonsillitis due to <i>S. pyogenes</i> (FDA approved in ages &ge;2 years and adults); treatment of community-acquired pneumonia due to susceptible organisms, including <i>C. pneumoniae</i>, <i>M. pneumoniae</i>, <i>H. influenzae</i>, <i>S. pneumoniae</i> (FDA approved in ages &ge;6 months and adults). [Oral azithromycin is not indicated for use in patients with pneumonia who have moderate to severe disease and judged to be inappropriate for oral therapy or have any risk factors such as cystic fibrosis, nosocomial infection, known or suspected bacteremia, hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia)]; treatment of sinusitis or COPD exacerbation due to <i>H. influenzae</i>, <i>M. catarrhalis</i>, or <i>S. pneumoniae</i> (FDA approved in adults); treatment of infections of the skin and skin structure, acute pelvic inflammatory disease, chancroid, and urethritis and cervicitis due to susceptible strains of <i>C. trachomatis</i>, <i>N. gonorrhoeae</i>, <i>M. catarrhalis</i>, <i>H. influenzae</i>, <i>S. aureus</i>, <i>S. pyogenes</i>, <i>S. pneumoniae</i>, <i>Mycoplasma pneumoniae</i>, <i>M. avium</i> complex, <i>C. psittaci</i>, and <i>C. pneumoniae</i> (FDA approved in adults). Has also been used for treatment of babesiosis, pertussis, endocarditis prophylaxis in penicillin allergic patients, for prophylaxis of peritonitis in patients undergoing invasive dental procedures, and cystic fibrosis lung disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (Zmax); oral suspension: Treatment of community-acquired pneumonia due to <i>C. pneumoniae, M. pneumoniae, H. influenzae, S. pneumonia</i> (FDA approved in ages &ge;6 months and adults); treatment of acute bacterial sinusitis due to <i>H. influenzae, M. catarrhalis, or S. pneumoniae</i> (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of community-acquired pneumonia due to susceptible <i>C. pneumoniae</i>, <i>L. pneumophilia</i>, <i>M. pneumoniae</i>, <i>H. influenzae</i>, <i>S. aureus</i>, <i>S. pneumoniae</i>; treatment of pelvic inflammatory disease due to susceptible <i>C. pneumonia</i>, <i>N. gonorrhoeae</i>, or <i>M. hominis</i> (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983163\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azithromycin may be confused with azathioprine, erythromycin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax may be confused with Fosamax, Zinacef, Zovirax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983246\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, fatigue, headache, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatitis (children), pruritus, skin photosensitivity, skin rash (single-dose regimens tend to be associated with increased incidence)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased serum bicarbonate (adults), decreased serum glucose (adults), increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum potassium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (single-dose regimens tend to be associated with increased incidence), anorexia, diarrhea (more common with single-dose regimens), dysgeusia, dyspepsia, flatulence, gastritis, loose stools (single-dose regimens tend to be associated with increased incidence), melena (adults, multiple-dose regimens), mucositis, nausea (more common with single-dose regimens), oral candidiasis, vomiting (children: Single-dose regimens tend to be associated with increased incidence; adults: More common with single 2 g dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Genital candidiasis (adults, multiple-dose regimens), vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Change in neutrophil count (children), decreased hematocrit (adults), decreased hemoglobin (adults), decrease in absolute neutrophil count (children: 500 to 1,500 cells/mm<sup>3</sup>), eosinophilia, increased neutrophils (adults), lymphocytopenia, thrombocythemia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local (adults with IV administration): Local inflammation, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, nephritis (adults, multiple-dose regimens)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal stools, acute generalized exanthematous pustulosis, acute renal failure, ageusia, aggressive behavior, agitation, alteration in sodium, altered sense of smell, altered serum glucose, anaphylaxis, anemia, angioedema, anosmia, anxiety, arthralgia, asthma, basophilia, bronchitis, cardiac arrhythmia, <i>Clostridium difficile</i> associated diarrhea, conjunctivitis (children), constipation, convulsions, cough, deafness, decreased serum potassium (children), decreased serum sodium, diaphoresis, DRESS syndrome, dyspnea, dysuria, eczema, edema, emotional lability, enteritis, erythema multiforme, exacerbation of myasthenia gravis, facial edema, flu-like symptoms (children), fungal dermatitis (children), fungal infection (children), gastrointestinal disease, hearing loss, hepatic failure, hepatic insufficiency, hepatic necrosis, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hostility, hyperactivity, hyperkinesia, hypersensitivity reaction, hypotension, increased monocytes, increased serum alkaline phosphatase, increased serum bicarbonate, increased serum phosphate, interstitial nephritis, insomnia, irritability, jaundice, Lambert-Eaton syndrome, leukopenia, maculopapular rash, malaise, nervousness, neutropenia, otitis media, pain, pancreatitis, paresthesia, pharyngitis, pleural effusion, prolonged Q-T interval on ECG, pseudomembranous colitis, pyloric stenosis, pyloric stenosis (infantile hypertrophic), rhinitis, seizure, Stevens-Johnson syndrome, syncope, thrombocytopenia, tinnitus, tongue discoloration, toxic epidermal necrolysis, urticaria, ventricular tachycardia, vesiculobullous dermatitis, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983221\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to azithromycin, erythromycin, other macrolide (eg, azalide or ketolide) antibiotics, or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> The manufacturer does not list concurrent use of pimozide as a contraindication; however, azithromycin is listed as a contraindication in the manufacturer&rsquo;s labeling for pimozide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983222\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Allergic reactions (eg, angioedema, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported (rare), including fatalities; reappearance of allergic reaction may occur shortly after discontinuation of symptomatic treatment without further azithromycin exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: Macrolides (especially erythromycin) have been associated with rare QTc prolongation and ventricular arrhythmias, including torsade de pointes; consider avoiding use in patients with prolonged QT interval, congenital long QT syndrome, history of torsade de pointes, bradyarrhythmias, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, uncompensated heart failure, or concurrent use of Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents or other drugs known to prolong the QT interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac risk: A retrospective cohort study done in Tennessee Medicaid patients demonstrated an increased cardiac risk with azithromycin relative to amoxicillin or ciprofloxacin, and similar risk compared to levofloxacin; notably, increased cardiac mortality (an estimated 47 additional deaths per 1 million 5-day courses of treatment compared to amoxicillin) was associated with higher baseline cardiovascular risk (Ray 2012); however, these data may not be generalizable to the population as a whole (Ray 1989). In another retrospective population study of US veterans, azithromycin was shown to significantly increase the risk of mortality and arrhythmia on days 1 to 5, but not on days 6 to 10 after dispensing the prescription (Rao 2014). In contrast, 2 additional large retrospective cohort studies did <b>not</b> demonstrate an increased risk of cardiovascular events, including all-cause mortality or cardiovascular death (Svanstrom 2013, Mortensen 2014). The implications of these data have yet to be determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD); CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gonorrhea/syphilis: May mask or delay symptoms of incubating gonorrhea or syphilis, so appropriate culture and susceptibility tests should be performed prior to initiating a treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with preexisting liver disease; hepatocellular and/or cholestatic hepatitis, with or without jaundice, hepatic necrosis, failure, and death have occurred. Discontinue immediately if symptoms of hepatitis occur (malaise, nausea, vomiting, abdominal colic, fever).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation and new onset of symptoms have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment (GFR &lt;10 mL/minute); increased gastrointestinal adverse effects may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infants: Use of azithromycin in neonates and infants (treatment up to 42 days of life) has been associated with infantile hypertrophic pyloric stenosis (IHPS); observe for non-bilious vomiting or irritability with feeding (Eberly 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral suspensions: Immediate release and extended release suspensions are not interchangeable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983249\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983250\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15943&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Azithromycin (Systemic) may enhance the QTc-prolonging effect of Amiodarone.  Management: The concomitant use of amiodarone, which has a high risk for QTc prolongation, with azithromycin, which may also prolong the QT interval, should be avoided.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Macrolide Antibiotics may enhance the QTc-prolonging effect of Cisapride. Macrolide Antibiotics may decrease the metabolism of Cisapride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Azithromycin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivermectin (Systemic): Azithromycin (Systemic) may increase the serum concentration of Ivermectin (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Lovastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May increase the serum concentration of Azithromycin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Azithromycin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983254\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Rate and extent of GI absorption may be altered depending upon the formulation. Azithromycin suspension, not tablet form, has significantly increased absorption (46%) with food. Management: Immediate release suspension and tablet may be taken without regard to food; extended release suspension should be taken on an empty stomach (at least 1 hour before or 2 hours following a meal).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983214\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983215\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Azithromycin crosses the placenta (Ramsey 2003). The maternal serum half-life of azithromycin is unchanged in early pregnancy and decreased at term; however, high concentrations of azithromycin are sustained in the myometrium and adipose tissue (Fischer 2012; Ramsey 2003). Azithromycin is recommended for the treatment of several infections, including chlamydia, gonococcal infections, and <i>Mycobacterium avium</i> complex (MAC) in pregnant patients (consult current guidelines) (CDC [Workowski 2015]; HHS [opportunistic; adult] 2015). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10585985\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, WBC with differential; number and type of stools/day for diarrhea; monitor patients receiving azithromycin and drugs known to interact with erythromycin (ie, theophylline, digoxin, anticoagulants, triazolam) since there are still very few studies examining drug-drug interactions with azithromycin. When used as part of alternative treatment for gonococcal infection, test-of-cure 7 days after dose (CDC, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983260\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983262\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid from the GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Extensive tissue; distributes well into skin, lungs, sputum, tonsils, and cervix; penetration into CSF is poor; V<sub>d</sub>: 31 to 33 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding (concentration dependent and dependent on alpha1-acid glycoprotein concentrations): Oral, IV: 7% to 51% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to inactive metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Tablet, immediate release oral suspension: 34% to 52%; extended release oral suspension: 28% to 43%; variable effect with food (increased with immediate or delayed release oral suspension, unchanged with tablet) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: Oral, IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 4 months to 15 years: 54.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: 68 to 72 hours; Extended release: 59 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: Immediate release: ~2 to 3 hours; Extended release: 3 to 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Oral, IV: Biliary (major route 50%, unchanged); urine (6% to 14% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983342\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Azithromycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (3): $87.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Zithromax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (3): $442.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Azithromycin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zithromax Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Azithromycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (15 mL): $34.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (30 mL): $34.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Zithromax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (15 mL): $174.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (22.5 mL): $174.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Zmax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $160.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Azithromycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (6): $46.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (3): $46.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (30): $560.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zithromax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $1,235.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $2,471.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (30): $2,965.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zithromax Tri-Pak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (3): $247.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zithromax Z-Pak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (6): $247.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961955\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ajustin (KR);</li>\n      <li>Aratro (ES);</li>\n      <li>Atizor (CL);</li>\n      <li>ATM-200 (TZ);</li>\n      <li>Aza-250 (HK);</li>\n      <li>Aza-500 (HK);</li>\n      <li>Azadose (FR);</li>\n      <li>Azas (KR);</li>\n      <li>Azath (KR);</li>\n      <li>Azatril (EE, VN);</li>\n      <li>Azax (TR);</li>\n      <li>Azbact (LK);</li>\n      <li>Azce (LK);</li>\n      <li>Azee (HK);</li>\n      <li>Azeemycin (PH);</li>\n      <li>Azenil (IL);</li>\n      <li>Azi-500 (PH);</li>\n      <li>Azibact (DE, IN);</li>\n      <li>Azibiot (LV, RO);</li>\n      <li>Azicine (HK, MY, VN);</li>\n      <li>Azilide-250 (PH);</li>\n      <li>Azilide-500 (PH);</li>\n      <li>Azimac (SA);</li>\n      <li>Azimax (MY);</li>\n      <li>Azimax-250 (HK, SG);</li>\n      <li>Azimed (HR);</li>\n      <li>Azin (BD, PH);</li>\n      <li>Azinobin (CO);</li>\n      <li>Aziphar (VN);</li>\n      <li>Azirocin (KR);</li>\n      <li>Azith (AU, TH);</li>\n      <li>Azithral (IN);</li>\n      <li>Azithrin (MT);</li>\n      <li>Azithro (MY);</li>\n      <li>Azithrom (TW);</li>\n      <li>Azitops (KR);</li>\n      <li>Azitrex (EC);</li>\n      <li>Azitrix (PT);</li>\n      <li>Azitrocin (IT, PH);</li>\n      <li>Azitromax (NO, SE);</li>\n      <li>Azitrox (SK);</li>\n      <li>Aziwok (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Azm (LK);</li>\n      <li>Azo-500 (PH);</li>\n      <li>Azomax (BH, KW);</li>\n      <li>Azomycin (AE, KW, QA, SA);</li>\n      <li>Azomyne (JO, LB, QA);</li>\n      <li>Azox (JO);</li>\n      <li>Azro (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Azromax (IE);</li>\n      <li>Aztrin (ID);</li>\n      <li>Azyth (PH);</li>\n      <li>Azytsyn (UA);</li>\n      <li>Binozyt (HK, KR, LK, SG, TH, VN);</li>\n      <li>Clindal AZ (BR, HK);</li>\n      <li>Cronopen (AR);</li>\n      <li>Decantin (PH);</li>\n      <li>Floctil (HK, MY, TH);</li>\n      <li>Geozif (VN);</li>\n      <li>Geozit (PH);</li>\n      <li>Glazi (VN);</li>\n      <li>Imexa (HK, MY);</li>\n      <li>Inedol (PE);</li>\n      <li>Jazit (PH);</li>\n      <li>Koptin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Kromicin (CO);</li>\n      <li>Macromax (PH);</li>\n      <li>Macrozit (CO, PE);</li>\n      <li>Maxmor (ID);</li>\n      <li>Mazit (QA);</li>\n      <li>Meithromax (TH);</li>\n      <li>Mezatrin (ID);</li>\n      <li>Neazi (VN);</li>\n      <li>OD Mac (PH);</li>\n      <li>Odazyth (BD);</li>\n      <li>Onzet (TH);</li>\n      <li>Ormaks (UA);</li>\n      <li>Shepherd (CN);</li>\n      <li>Sumamed (BG, CN, CZ, EE, LV, PL, SK);</li>\n      <li>Thromaxin (PH);</li>\n      <li>Tromix (CO);</li>\n      <li>Ultreon (DE);</li>\n      <li>Uzet (LK);</li>\n      <li>Vinzam (BD);</li>\n      <li>Weihong (CN);</li>\n      <li>Wiltrozin (PH);</li>\n      <li>Xithrone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Zaha-250 (TZ);</li>\n      <li>Zaret (CO);</li>\n      <li>Zarom (ID);</li>\n      <li>Zedbac (GB);</li>\n      <li>Zedd (AU);</li>\n      <li>Zemax (TH);</li>\n      <li>Zenith (PH);</li>\n      <li>Zeto (IL);</li>\n      <li>Zetron (LB, QA);</li>\n      <li>Zicho (ID);</li>\n      <li>Zimac (SA);</li>\n      <li>Zimax (LB);</li>\n      <li>Zimericina (CO);</li>\n      <li>Zinfect (TR);</li>\n      <li>Zistic (ID);</li>\n      <li>Zitaspen (ZW);</li>\n      <li>Zithrax (ID);</li>\n      <li>Zithromac SR (JP);</li>\n      <li>Zithromax (AE, AT, AU, BB, BD, BF, BH, BJ, CH, CI, CL, CN, CR, CY, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, ID, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PH, PK, PT, PY, QA, SA, SC, SD, SE, SG, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Zithromax IV (MY, SG);</li>\n      <li>Zithrox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LK, LY, OM, SA, SY, YE);</li>\n      <li>Zitrim (CO);</li>\n      <li>Zitrocin (PY);</li>\n      <li>Zitrolin (ID);</li>\n      <li>Zitromax (AR, BE, BR, DK, EC, ES, IS, IT, LU, PE, TR, UY, VE);</li>\n      <li>Zmax (IL, SG, ZW);</li>\n      <li>Zmax One Dose (PH);</li>\n      <li>Zocin (AE, JO, QA);</li>\n      <li>Zomax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zymed (ID);</li>\n      <li>Zynomax (MY);</li>\n      <li>Zythrocin (TW);</li>\n      <li>Zytroks (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012 [published correction appears in http://aapredbook.aappublications.org/site/misc/errata12.xhtml</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &quot;ACOG Practice Bulletin No. 120: Use of Prophylactic Antibiotics in Labor and Delivery,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1472-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azithromycin monohydrate powder [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ballard HO, Anstead MI, and Shook LA, &quot;Azithromycin in the Extremely Low Birth Weight Infant for the Prevention of Bronchopulmonary Dysplasia: A Pilot Study,&quot; <i>Respir Res</i>, 2007, 8:41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17550598/pubmed\" target=\"_blank\" id=\"17550598\">17550598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bryant KA, Humbaugh K, Brothers K, et al, &quot;Measures to Control an Outbreak of Pertussis in a Neonatal Intermediate Care Nursery After Exposure to a Healthcare Worker,&quot; <i>Infect Control Hosp Epidemiol</i>, 2006, 27(6):541-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16755471/pubmed\" target=\"_blank\" id=\"16755471\">16755471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,&quot; <i>MMWR Recomm Rep</i>, 2005, 54(RR-14):1-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16340941/pubmed\" target=\"_blank\" id=\"16340941\">16340941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections,&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 2012, 61(31):590-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22874837/pubmed\" target=\"_blank\" id=\"22874837\">22874837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &quot;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&quot; <i>Clin Infect Dis</i>, 2012 54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen R. Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis. <i>Pediatr Infect Dis J</i>. 2004;23(2 Suppl):S129-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14770076/pubmed\" target=\"_blank\" id=\"14770076\">14770076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents, &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drew RH and Gallis HA, &ldquo;Azithromycin-Spectrum of Activity, Pharmacokinetics, and Clinical Applications,&rdquo; <i>Pharmacotherapy</i>, 1992, 12(3):161-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/1319048 /pubmed\" target=\"_blank\" id=\"1319048 \">1319048 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DuPont HL, &quot;Clinical Practice. Bacterial Diarrhea,&quot; <i>N Engl J Med</i>, 2009, 361(16):1560-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19828533/pubmed\" target=\"_blank\" id=\"19828533\">19828533</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer JH, Sarto GE, Habibi M, et al, &quot;Influence of Body Weight, Ethnicity, Oral Contraceptives, and Pregnancy on the Pharmacokinetics of Azithromycin in Women of Childbearing Age,&quot; <i>Antimicrob Agents Chemother</i>, 2012, 56(2):715-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22106226/pubmed\" target=\"_blank\" id=\"22106226\">22106226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foulds G, Shepard RM, and Johnson RB, &ldquo;The Pharmacokinetics of Azithromycin in Human Serum and Tissues,&rdquo; <i>J Antimicrob Chemother</i>, 1990, 25(Suppl A):73-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/2154441/pubmed\" target=\"_blank\" id=\"2154441\">2154441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al, &quot;Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,&quot; <i>Circulation</i>, 2009, 119(11):1541-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19246689/pubmed\" target=\"_blank\" id=\"19246689\">19246689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein LH, Berlin M, Tsur L, et al, &quot;The Safety of Macrolides During Lactation,&quot; <i>Breastfeed Med</i>, 2009, 4(4):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19366316/pubmed\" target=\"_blank\" id=\"19366316\">19366316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hammerschlag MR, Gelling M, Roblin PM, Kutlin A, Jule JE. Treatment of neonatal chlamydial conjunctivitis with azithromycin. <i>Pediatr Infect Dis J</i>. 1998;17(11):1049-1050.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/9849993 /pubmed\" target=\"_blank\" id=\"9849993 \">9849993 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &quot;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&quot; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. April 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed May 21, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobs RF, Maples HD, Aranda JV, et al, &quot;Pharmacokinetics of Intravenously Administered Azithromycin in Pediatric Patients,&quot; <i>Pediatr Infect Dis J</i>, 2005, 24(1):34-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/15665708/pubmed\" target=\"_blank\" id=\"15665708\">15665708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelsey JJ, Moser LR, Jennings JC, et al, &quot;Presence of Azithromycin Breast Milk Concentrations: A Case Peport,&quot; <i>Am J Obstet Gynecol</i>, 1994, 170(5 Pt 1):1375-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8178871/pubmed\" target=\"_blank\" id=\"8178871\">8178871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al, &quot;The Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lockwood AM, Cole S, and Rabinovich M, &quot;Azithromycin-Induced Liver Injury,&quot; <i>Am J Health Syst Pharm</i>, 2010, 67(10):810-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20479103/pubmed\" target=\"_blank\" id=\"20479103\">20479103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. <i>BMJ</i>. 2014;348:1908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24618148/pubmed\" target=\"_blank\" id=\"24618148\">24618148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mackell S, &quot;Traveler's Diarrhea in the Pediatric Population: Etiology and Impact,&quot; <i>Clin Infect Dis</i>, 2005, 41(Suppl 80):S547-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16267717/pubmed\" target=\"_blank\" id=\"16267717\">16267717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23540878/pubmed\" target=\"_blank\" id=\"23540878\">23540878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. <i>JAMA</i>. 2014;311(21):2199-2208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24893087/pubmed\" target=\"_blank\" id=\"24893087\">24893087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahata MC, Koranyi KI, Gadgil SD, et al, &ldquo;Pharmacokinetics of Azithromycin After Oral Administration of Multiple Doses of Suspension,&rdquo; <i>Antimicrob Agents Chemother</i>, 1993, 37(2):314-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8383944 /pubmed\" target=\"_blank\" id=\"8383944 \">8383944 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Doherty B. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group.<i> Eur J Clin Microbiol Infect Dis</i>. 1996;15(9):718-724.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8922571/pubmed\" target=\"_blank\" id=\"8922571\">8922571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramsey PS, Vaules MB, Vasdev GM, et al, &quot;Maternal and Transplacental Pharmacokinetics of Azithromycin,&quot; <i>Am J Obstet Gynecol</i>, 2003, 188(3):714-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17123995/pubmed\" target=\"_blank\" id=\"17123995\">17123995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. <i>American Journal of Epidemiology</i>. 1989;129(4):837-849.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/2646920/pubmed\" target=\"_blank\" id=\"2646920\">2646920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray WA, Murray KT, Hall K, et al, &quot;Azithromycin and the Risk of Cardiovascular Death,&quot; <i>N Engl J Med</i>, 2012, 366(20):1881-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22591294/pubmed\" target=\"_blank\" id=\"22591294\">22591294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saiman L, Anstead M, Mayer-Hamblett N, et al, &quot;Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With <i>Pseudomonas aeruginosa</i>: A Randomized Controlled Trial,&quot; <i>JAMA</i>, 2010, 303(17):1707-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20442386/pubmed\" target=\"_blank\" id=\"20442386\">20442386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saiman L, Marshall BC, Mayer-Hamblett N, et al, &ldquo;Azithromycin in Patients With Cystic Fibrosis Chronically Infected With <i>Pseudomonas aeruginosa</i>: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2003, 290(13):1749-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14519709 /pubmed\" target=\"_blank\" id=\"14519709 \">14519709 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>, 2014; 58(10):1496]. <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(6):455-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/7667049/pubmed\" target=\"_blank\" id=\"7667049\">7667049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. <i>Am J Obstet Gynecol</i>. 2015;212(6):812.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25595580/pubmed\" target=\"_blank\" id=\"25595580\">25595580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Svanstr&ouml;m H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. <i>N Engl J Med</i>. 2013;368(18):1704-1712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23635050/pubmed\" target=\"_blank\" id=\"23635050\">23635050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &quot;Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&quot; <i>Circulation</i>, 2007, 116(15):1736-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &quot;Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae Type 1,&quot; 2005. Available at http://whqlibdoc.who.int/publications/2005/9241592330.pdf </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15943 Version 241.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7983183\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F7983184\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10585820\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12824328\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10585964\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7983340\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F7983186\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10585984\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F7983256\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10585821\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7983163\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7983246\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7983221\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7983222\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F7983249\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7983250\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F7983254\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F7983214\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7983215\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10585985\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7983260\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F7983262\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F7983342\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961955\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15943|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=azithromycin-systemic-drug-information\" class=\"drug drug_general\">Azithromycin (systemic): Drug information</a></li><li><a href=\"topic.htm?path=azithromycin-systemic-patient-drug-information\" class=\"drug drug_patient\">Azithromycin (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}